Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation.
Primary cytomegalovirus infection in the patient who is receiving immunosuppression therapy is associated with a high morbidity and mortality. We report a patient who developed primary cytomegalovirus infection 37 days after heart transplantation with a rapidly deteriorating course. Treatment with the new antiviral drug trisodium phosphonoformate (Foscarnet-Astra) was initiated as a lifesaving measure with rapid, dramatic improvement in the patient's condition and subsequent recovery.
D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D017245:Foscarnet; D016027:Heart Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011183:Postoperative Complications
D009943:Organophosphorus Compounds; D017245:Foscarnet; D010746:Phosphonoacetic Acid